AMH Clinical Trial
Official title:
Low Anti-mullerian Hormone and Pregnancy Outcome in IVF
Verified date | October 2020 |
Source | Al Baraka Fertility Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Anti-Mu¨llerian hormone (AMH) is an established marker of ovarian reserve (La Marca et al., 2010; Nelson et al., 2009) and predicts both high and low responses in ovarian stimulation cycles (Eldar-Geva et al., 2005; Nardo et al., 2009; Nelson et al., 2007). Presently, AMH helps clinicians counsel patients prior to IVF treatment (La Marca et al., 2011), despite the fact that it fails to predict who will become pregnant (Lamazou et al., 2011; Riggs et al., 2011). It has been demonstrated that poor responders can achieve both pregnancy and live birth (Weghofer et al., 2011). There are few studies regarding extremely low AMH concentrations and live births (Fraisse et al., 2008; Tocci et al., 2009; Weghofer et al., 2011) and they present either a small number of patients or limited data describing the groups of investigated patients. Another factor affecting pregnancy rates is endometriosis, a chronic gynaecological disease characterized by the presence of functional endometrial tissue outside the uterine cavity (Koninckx et al., 1991). Many studies have reported that pregnancy rates are lower in women with endometriosis than in controls (Gupta et al., 2008; Koninckx et al., 1991 Pellicer et al., 2000). Lower AMH serum concentrations are associated with endometriosis severity (Shebl et al., 2006). The primary objective of the present study was to assess the clinical pregnancy rates in women with extremely low AMH concentrations with respect to age.
Status | Not yet recruiting |
Enrollment | 650 |
Est. completion date | November 25, 2020 |
Est. primary completion date | November 20, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 22 Years to 45 Years |
Eligibility | Inclusion Criteria: Women =22 years age AMH is 0.5 and less Body mass index- 18.5-30 kg/m 2 The normal uterine cavity on ultrasound scan At least one good quality embryo present for transfer Women willing to comply with the clinical study protocol Exclusion Criteria: - Women = 45 years age - AMH >0.5 - Uterine abnormalities that can compromise the IRs (e.g., endometrial polyp, fibroids, hydrosalpinx, and adenomyosis) - Endocrine dysfunction or organ dysfunction such as liver or kidney failure. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Al Baraka Fertility Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | pregnancy test | B-HCG | 2 weeks | |
Primary | clinical pregnancy rate | fetal heart activity | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05592730 -
AMHR2 Polymorphism in Blood and Granulosa Cells in Unexplained Infertility
|
||
Completed |
NCT04639505 -
Predictive Value of New AMH Test Method for Ovarian Response
|
||
Completed |
NCT03220594 -
Serum AMH Levels in Patients Who Underwent Hypogastric Artery Ligation
|
N/A | |
Not yet recruiting |
NCT06426771 -
Effect of Antimullerian Hormone Levels on the Inflammatory Index, Phytochemical Index and NRF Nutrient Density
|
||
Recruiting |
NCT02785809 -
Ovarian Function and Reserve Parameters After Discontinuation of Long-term Use of Oral Contraception
|
N/A | |
Recruiting |
NCT04927676 -
Hormones in Hypogonadotropic Hypogonadism
|